Corpus Intelligence IC Memo — WENTWORTH DOUGLASS HOSPITAL 2026-04-26 09:05 UTC
IC Memo — WENTWORTH DOUGLASS HOSPITAL
Investment Committee Memorandum | NH | 118 beds | Grade B | EBITDA uplift $36.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WENTWORTH DOUGLASS HOSPITAL

CCN 300018 | nan, NH | 118 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

WENTWORTH DOUGLASS HOSPITAL is a 118-bed suburban community hospital in nan, NH with $500.9M in net patient revenue and a 10.7% operating margin. The hospital serves a payer mix of 35.4% Medicare, 4.7% Medicaid, and 59.9% commercial.

Thesis: Turnaround. Our ML models identify $36.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 10.7% to 18.0% (+736bps).

Net Revenue HCRIS$500.9M
Current EBITDA COMPUTED$53.5M
Operating Margin COMPUTED10.7%
Occupancy HCRIS101.4%
Revenue / Bed COMPUTED$4.2M
Net-to-Gross HCRIS29.3%
Distress Probability ML32.9%

2. Market Context & Competitive Position

30
NH Hospitals
-2.7%
State Median Margin
12
Comparable Hospitals

NH has 30 Medicare-certified hospitals with a median operating margin of -2.7%. The target's margin of 10.7% places it above the state median. Among 12 size-comparable peers (59-236 beds), the median margin is -2.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (59-236), prioritizing same-state peers. 12 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WENTWORTH DOUGLASS HOSPITAL (Target)NH118$500.9M10.7%
ELLIOT HOSPITALNH215$660.8M14.5%
CONCORD HOSPITAL INC.NH206$553.5M-5.1%
PORTSMOUTH REGIONAL HOSPITALNH168$347.4M45.5%
SOUTHERN NH MEDICAL CENTERNH138$293.0M-0.8%
EXETER HOSPITAL INC.NH99$282.0M-3.2%
ST. JOSEPH HOSPITALNH160$236.2M-15.1%
CHESHIRE MEDICAL CENTERNH86$236.2M-22.4%
PARKLAND MEDICAL CENTERNH68$158.7M47.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $36.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$10.5M+210bp18mo
Cost to Collect4.5%2.5%$10.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.1M+122bp9mo
Clean Claim Rate88.0%96.0%$321K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$10.5M
Cost to Collect
$10.0M
Denial Rate Reduction
$9.9M
A/R Days Reduction
$6.1M
Clean Claim Rate
$321K
Total EBITDA Uplift$36.9M
Current EBITDA$53.5M
+ RCM Uplift+$36.9M
Pro Forma EBITDA$90.4M
Current Margin10.7%
Pro Forma Margin18.0%
WC Released (1x)$19.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$82.4M$721.8M8.76x54.4%
Base (11x exit)10.0x11.0x$82.4M$820.7M9.96x58.4%
Bull Case9.0x11.0x$74.1M$969.2M13.07x67.2%
Bull (12x exit)9.0x12.0x$74.1M$1.08B14.56x70.9%
Bear Case11.0x10.0x$90.6M$510.7M5.64x41.3%
Bear (11x exit)11.0x11.0x$90.6M$591.2M6.53x45.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 12 hospitals with 59-236 beds
  • Same-state prioritization (n=13)
  • Comp margins: P25=-10.7% / P50=-2.0% / P75=10.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.